Lenz-Majewski syndrome (LMS) is a rare disease characterized by complex craniofacial, dental, cutaneous, and limb abnormalities combined with intellectual disability. Mutations in the PTDSS1 gene coding one of the phosphatidylserine (PS) synthase enzymes, PSS1, were described as causative in LMS patients. Such mutations render PSS1 insensitive to feedback inhibition by PS levels. Here we show that expression of mutant PSS1 enzymes decreased phosphatidylinositol 4-phosphate (PI4P) levels both in the Golgi and the plasma membrane (PM) by activating the Sac1 phosphatase and altered PI4P cycling at the PM. Conversely, inhibitors of PI4KA, the enzyme that makes PI4P in the PM, blocked PS synthesis and reduced PS levels by 50% in normal cells. However, mutant PSS1 enzymes alleviated the PI4P dependence of PS synthesis. Oxysterol-binding protein-related protein 8, which was recently identified as a PI4P-PS exchanger between the ER and PM, showed PI4P-dependent membrane association that was significantly decreased by expression of PSS1 mutant enzymes. Our studies reveal that PS synthesis is tightly coupled to PI4P-dependent PS transport from the ER. Consequently, PSS1 mutations not only affect cellular PS levels and distribution but also lead to a more complex imbalance in lipid homeostasis by disturbing PI4P metabolism. phosphatidylserine | phosphatidylinositol | PI 4-kinase | ER-PM junctions | lipid transfer Author contributions: M.S. and T.B. designed research; M.S., P.I., Y.J.K., and T.B. performed research; D.J.T. and P.V. contributed new reagents/analytic tools; M.S., P.I., H.A.B., Y.J.K., and T.B. analyzed data; and T.B. wrote the paper.
M aintenance of the unique lipid composition of different eukaryotic cell membranes requires a concerted regulation of lipid synthesis and transport via vesicular trafficking and nonvesicular lipid transfer (1) (2) (3) . Most lipids in the cell are synthesized in the endoplasmic reticulum (ER) or taken up from the outside for degradation and reutilization via the endo-lysosomal system. Lipid synthesis is often under strict feedback control, and therefore transport of lipids away from the site of synthesis is a key regulator of lipid synthesis. The importance of such feedback control is highlighted by the disease Lenz-Majewski syndrome (LMS) (4) . LMS is characterized by multiple skeletal dysplasiadysostosis, with characteristic craniofacial and limb abnormalities combined with intellectual disabilities (5) . Recent studies have identified mutations in the PTDSS1 gene in LMS patients and showed that these mutations render the enzyme PSS1 resistant to feedback inhibition by phosphatidylserine (PS) (6) .
Recent studies have shown that directional PS transport between the ER and plasma membrane (PM) can be driven by the PI4P gradient formed between the two membranes (7, 8) . This gradient is set up by the actions of PI4KA, one of four phosphatidylinositol 4-kinases (PI4Ks), which functions in the PM (9) and the PI4P phosphatase, Sac1, located in the ER and the Golgi (10) . While studying the role of phosphoinositides in the control of lipid metabolism, we found that uncontrolled PS production had an impact on lipid homeostasis by affecting phosphatidylinositol 4-phosphate (PI4P) cycling between the PM and the ER.
Results and Discussion PI4KA Inhibitors Inhibit PS Synthesis. These studies were initiated to test our hypothesis that a PI4P gradient between the PM and the ER may be involved in the transport of specific lipids out of the ER (11) (Fig. 1F ). To determine whether PM PI4P production has any bearing on the level of any of the phospholipid classes, we performed lipidomic analysis of HEK293 cells treated for 30 h with the PI4KA specific inhibitor A1 (12) . We found that the cellular level of PS was consistently decreased by about 50% in cells treated with A1 compared with controls ( Fig. 1A) . This effect was specific in that inhibition of PI4KB, another PI4K that works primarily at the Golgi, had no effect on the levels of the major phospholipids (Fig. 1A) . The reduction in PS mass by A1 and other PI4KA inhibitors was caused by decreased synthesis as shown by a reduced [ 3 H]serine incorporation into PS in intact HEK293 cells ( Fig. 1 B and C) . The effectiveness of inhibitors on PS synthesis showed good correlation with their inhibitory potencies against PI4KA (Fig. 1C ). Importantly, A1 did not affect [ 3 H]serine uptake ( Fig. 1D ) so the inhibitory effect was truly on PS synthesis.
Effect of PI4KA Inhibitors on PS Synthesis Is Indirect. It has been shown previously that PS synthesis is under strong product inhibition (13) . Therefore, we reasoned that interfering with PI4KA function might have affected PS synthesis indirectly by blocking the transport of PS from the ER. PS is synthesized by two enzymes, PSS1 and PSS2, by head-group exchange from phosphatidylcholine (PC) and phosphatidylethanolamine (PE), respectively ( Fig. 1E ). If inhibition of PS synthesis by PI4KA inhibition were related to a transport defect, one would expect that PSS1 enzymatic activity in membrane preparations would Significance Phosphatidylserine (PS) is synthesized in the endoplasmic reticulum by PS synthase enzymes, but most of the PS is found in the inner leaflet of the plasma membrane. The importance of the present findings is that they uncover a critical connection between PI4P turnover and PS transport and demonstrate that uncontrolled PS synthesis as seen in Lenz-Majewski syndrome patients has deleterious consequences to cells affecting other lipids and not just PS.
not be sensitive to PI4K inhibition. Fig. 1J shows that A1 was indeed without effect on PS synthase activity of membrane preparations obtained from cells expressing the PSS1 enzyme. It is important to emphasize that the PI4KA inhibitor A1 inhibited PS synthesis only in intact cells and not the PSS1 enzyme itself. Next we tested the effects of A1 in cells expressing mutant PSS1 enzymes described in LMS (6) that are insensitive to PS-mediated negative feedback. If the A1 effect were indeed due to ER retention of PS, such mutant enzymes should be resistant to PI4KA inhibition even in the intact cells. As shown in Fig. 1H , expression of mutant PSS1 enzymes (L265P, P269S, and Q353R) elicited a very robust increase in PS synthesis in intact cells, significantly higher than the wild-type protein. Importantly, A1 treatment only slightly decreased PS synthesis in such cells (Fig. 1I) ; the small effect was attributed to inhibition of the endogenous enzyme. Notably, expression of PSS2 enzyme increased the synthesis of a faster running PS species, which was also less inhibited by the PI4K inhibitor ( Fig. 1 H and I) . Next we examined the effects of the PSS1 mutations on the distribution of PS using the LacC2 PS reporter (14) ( Fig. 2A ). It has been well documented that PS is found mostly in the PM and some endosomes as visualized by the LacC2 reporter (14) despite the fact that PS is synthesized in the ER. As shown in Fig.  2B , even when we overexpressed PSS1 or -2, there was no sign that PS was present in the ER. In contrast, overexpression of the PSS1 mutant enzymes has profoundly changed PS distribution, which now shows clearly detectable ER localization ( Fig. 2 C-E). Some mutants, namely P269S, also generated large vesicles positive for PS ( Fig. 2D ). These results suggested that PS is very efficiently transported out of the ER but appears in the ER when the PSS1 enzyme loses its product inhibition. These results also supported the notion that PS synthesis is very tightly coupled to PS transport out of the ER. If PI4KA-Sac1-mediated cycling is important for PS transport between the ER and the PM as shown recently (7, 8) , then inhibition of PI4KA is expected to impact PS levels in the PM. To test if this was indeed the case, we used a The quantification from two experiments with the range of the two determinations. Values were normalized to GFP-transfected controls. (J) PSS1 activity measurements in membranes prepared from COS-7 cells transfected with vector or PSS1-GFP wild-type enzyme. Note the lack of effect of the PI4KA inhibitor A1 (100 nM) in these membrane assays (means ± SEM from three membrane preparations assayed in duplicate).
recently developed bioluminescence resonance energy transfer (BRET) approach to monitor the level of PS in the PM using the LacC2 reporter (15) ( Fig. 3A) . A1 treatment induced a small but reproducible decrease in PM PS levels ( Fig. 3B ) consistent with a decreased transport from the ER (note that the BRET signal increases with time in DMSO-treated controls). Given the high level of PS in the membrane, it may require a longer time to achieve a more substantial decrease.
PS Overproduction Increases Sac1 Activity and Reduces PI4P Levels.
Having established the mechanism by which PI4KA controls PS synthesis, we wanted to know how PS overproduction affects PI4P metabolism. It has been described that PS stimulates the enzymatic activity of recombinant Sac1, the enzyme that dephosphorylates PI4P in the ER (16) . Similarly, yeast strains defective in PS synthesis show decreased Sac1 activity (16) . Therefore, we measured Sac1 activity in crude membranes prepared from cells overexpressing PSS1 mutant enzymes and compared them to vector-transfected controls. Fig. 3C shows that expression of PSS1-P269S has significantly increased the Sac1 activity of membranes. We then measured PI4P levels specifically in various compartments using immunostaining techniques (17) in HEK293 cells expressing the mutant PSS1-P269S enzyme. Quantification of the immunostained images showed significantly reduced levels of PI4P both in the Golgi and the PM in cells expressing the mutant PSS1-GFP relative to those expressing GFP only ( Fig. 3 D-G). This was consistent with the increased Sac1 activity reducing the levels of PI4P in membranes from where PI4P is either delivered to the ER or where Sac1 can directly access PI4P.
The PS-Transport Protein ORP8 Is Affected by PM PI4P and ER PS Production. Recent studies identified the oxysterol-binding protein-related proteins ORP8 and ORP5 (and OSH6 in yeast) as capable of transporting PS from the ER to the PM in exchange for PI4P moving in the other direction (7, 8) . Therefore, we investigated the effects of overproduction of PS by PSS1-P269S on this lipid exchange process. First, we examined whether knocking down these ORP proteins affected PI4P in the PM (PI4P pm ). If these ORP proteins deliver PI4P from the PM to the Sac1 phosphatase in the ER, their depletion may affect the rate of PI4P disappearance from the PM after inhibition of PI4KA. We followed the kinetics of PI4P pm changes after inhibition of PI4KA using the BRET approach (15) ( Fig. 4 A and B) . As expected, A1 treatment led to a steady decline of PI4P pm . Knockdown of ORP5 had only a minor effect on either the resting BRET signal or the kinetics of decline after A1 treatment. In contrast, ORP8 knockdown increased the basal BRET signal and slowed down the PI4P pm decrease. Combined knockdown of both ORP proteins had the largest effect, increasing the resting BRET signal and slowing the decay (Fig. 4C) . These results were consistent with the recent data of Chung et al. (7) and suggested a redundant and complementary role of these ORP5 and ORP8 proteins in delivering PI4P to the ER for the Sac1 phosphatase. However, these data also suggested that PI4P is removed from the PM by additional mechanism(s) either by other PI4P transfer proteins or by the resting phospholipase C activity of the PM. Overexpression of PSS1-P269S decreased the basal BRET signal and significantly slowed down the rate of PI4P pm decrease (Fig. 4D ). PSS1 wild-type overexpression did not have a similar effect: in fact, it slightly elevated the BRET signal and, accordingly, delayed the PI4P pm decline (Fig. 4D ). As expected, Sac1 overexpression increased PI4P pm decline after PI4KA inhibition, suggesting that it is the Sac1 activity and not the access to PI4P, which limits the PI4P clearing process. These data suggested that the PI4P transfer process was reduced in cells overproducing PS and that it was not a simple consequence of Sac1 activation. To determine if PS overproduction down-regulated ORP5 or ORP8, we measured the levels of both ORP5 and ORP8 mRNAs by qPCR in cells expressing wild-type or mutant PSS1 enzymes. This analysis showed no significant reductions in the mRNA level ( Fig. 4E) . However, the number of contact sites between the PM and ORP8 was significantly reduced in cells expressing the mutant PSS1 enzyme relative to the wild type ( Fig. 4F ). ORP8 and ORP5 contacts the PM via their PH domains through interaction with PI4P (7) . In agreement with those findings, acute A1 treatment eliminated the ER-PM contacts of ORP8 as judged by total internal reflection fluorescence (TIRF) microscopy ( Fig. 4G ). Therefore, the reduced level of PI4P in the PM observed after PSS1-P269S overexpression could explain the reduced number of ORP8 PM contacts. These findings together strongly suggested that cells have implemented a protective mechanism to spare PI4P in the PM against a massively overproduced PS by limiting the delivery of PI4P from the PM to the ER for the Sac1-phosphatase.
In summary, the present studies have revealed a tight relationship between PS metabolism and PI4P turnover at ER-PM contact sites. Critical elements of this regulatory loop are the product inhibition of the PSS1 enzyme by PS, the activation of Sac1 by PS, and the PI4P-dependent transport of PS from the ER. Mutations that render the PSS1 enzyme resistant to product inhibition derail this process, putting a strain on PI4P turnover at the ER-PM junctions. The LMS causing mutations are located in the predicted ER luminal side of the PSS1 enzyme, suggesting that PS exerts its inhibitory effect on the luminal side. However, PS clearly accumulates on the cytoplasmic surface of the ER when mutant PSS1 enzymes are expressed and that is where it can activate the Sac1 enzyme. This raises the question of the role of PS flippases in connecting these metabolic control steps (18) . Although overproduced PS activates the Sac1 enzyme, it negatively affects ORP8/5-mediated PI4P delivery to the ER, which likely serves as a protective mechanism to spare the PM phosphoinositide pools. Because Sac1 also controls PI4P levels in the Golgi, PS overproduction also affects Golgi PI4P pools and hence is expected to impact the transport of cholesterol (19, 20) , ceramide (21) , and complex sphingolipids (22) . A tight relationship between Sac1-mediated PI4P cycle and PS synthesis has been described in yeast (23) . These studies suggest evolutionary conservation of the tight relationship between PS and PI4P metabolism. Our studies highlight the complexity of lipid changes that are caused by a single mutation that renders the PSS1 enzyme resistant to product inhibition, offering deeper insight into the complex pathology of the LMS disease. 
Materials and Methods
Materials and DNA Constructs. All materials and DNA constructs are listed in SI Materials and Methods. Primers used for cloning of DNA constructs are listed in Table S1 .
Cell Culture and Transfection. The HEK293-AT1 cells, a line that stably expresses the rat AT1a angiotensin receptor, have been described previously (24) . HEK293-AT1 and COS-7 cells were grown in Dulbecco's Modified Eagle Medium (DMEM-high glucose) containing 10% (vol/vol) FBS and 1% penicillin-streptomycin. For the metabolic labeling experiments, cells were seeded in 12-well plates (300,000 cells/well) and transfected with 0.3 μg DNA/well with Effectene Transfection Reagent (Qiagen). For live-cell imaging, cells were plated on glass coverslips, which were precoated with poly-Llysine solution (Sigma P8920) in six-well plates (500,000 cells/well). A total of 0.2 μg of DNA/well was used for six-well transfection with Effectene Transfection Reagent. For the Sac1 phosphatase activity assay, COS-7 cells were plated in 10-cm tissue culture dishes (1,000,000 cells/well) and transfected with 2 μg DNA/dish using the Effectene Transfection Reagent.
Lipidomic Analysis. Glycerophospholipids from pellets of HEK293-AT1 cells treated with different inhibitors were extracted using a modified Bligh and Dyer procedure (25) . Briefly, each pellet was homogenized in 800 μL of icecold 0.1 N HCl:CH3OH(1:1) and extracted and analyzed as detailed in SI Materials and Methods. Cells were kept on ice for 30 min, scraped by pipette tips, collected in polypropylene tubes, and centrifuged. The pellets were subjected to lipid extraction and lipids were analyzed by TLC essentially as described previously (26) . TLC plates were sprayed with EN3HANCE Spray (Perkin-Elmer) for autoradiography. For the quantitative analysis spots were scraped from the TLC plates, and the radioactivity was quantified by scintillation counter. In a few experiments extracted lipids were directly subjected to scintillation spectrometry as the major radioactive species was PS. For measurement of serine uptake, cells were seeded and treated with inhibitors as described above and labeled with L- Immunocytochemistry. For immunostaining, cells were plated on glass coverslips and transfected with the indicated DNAs for 48 h. For A1 treatment (100 nM, 1 h) cells were treated in serum-free DMEM before the staining procedure. Cells were washed with PBS and subjected to the fixation and staining protocol described for optimal PI4P staining in PM or Golgi as described by Hammond et al. (17) with slight modifications as detailed SI Materials and Methods.
Analysis of L-[ 3 H]Serine
Sac1 Phosphatase Assay. COS-7 cells were seeded on 10-cm culture dishes and transfected with plasmid DNAs encoding GFP, PSS1(P269S)-GFP, or GFP-Sac1. After 48 h, cells were washed with the modified Krebs-Ringer buffer and lysed with 2 mL of reaction buffer (200 mM sodium acetate, 50 mM Pipes, pH 6.8, and 20 μg/mL porcine gelatin) and broken up by passing through a 25-gauge syringe needle 10 times. After centrifugation at 1,000 × g at 4°C for 10 min, the supernatant was subjected to ultracentrifugation at 100,000 × g at 4°C for 1 h. The pellet was resuspended in a 200-μL reaction buffer, and the protein concentration was measured by BCA assay. Lysates (6-16 μg) were mixed with a reaction buffer of 20 μL final volume for the dephosphorylation reaction. PI4P dissolved in reaction buffer was added as substrate to a final concentration of 100 μM. Reactions were run at RT for 30 min and terminated by 20 μL of 100 mM N-ethylmaleimide. Samples were centrifuged at 14,000 × g at 4°C for 15 min in a microcentrifuge and the phosphate content of the supernatant was analyzed by a malachite green assay kit (Echelon). The free phosphate amount was calculated based on a standard curve after absorbance measurement at 620 nm. The PH domain of these proteins binds PI4P at the PM, and their C-terminal transmembrane domains anchor the protein to the ER (7) . (C) BRET analysis of PM PI4P changes after A1 (30 nM) treatment in HEK293-AT1 cells treated with siRNAs for ORP5, ORP8, or both. Grand means ± SEM is shown from three independent experiments performed in triplicates and normalized to the first point after addition of the inhibitor in control siRNA-treated cells. (D) Similar experiment shown for changes in PM PI4P in cells overexpressing mCherry-tagged versions of PSS1 wild type, P269S mutant, or Sac1. Grand means ± SEM is shown from three independent experiments performed in triplicates and normalized to the first point before addition of the inhibitor in the control cells. The rapid drop in the BRET signal is an artifact caused by the removal of the plate for stimulation. (E) Quantitative PCR of ORP5 and ORP8 proteins in cells expressing wild-type or P269S mutant PSS1-GFP. Means and whiskers are shown from five independent knockdown experiments (ORP5: PSS1wt vs. vector P = 0.051; PSS1P269S vs. vector P = 0.309; ORP8: PSS1wt vs. vector P = 0.023; PSS1P269S vs. vector P = 0.089, unpaired t test) (F) Quantification of the number of GFP-ORP8 puncta per foot-print area in TIRF analysis. Means and whiskers are shown from 67 and 133 cells expressing the wild-type or mutant PSS1-mCherry enzyme, respectively. Values were normalized to the average of the group expressing the wild-type enzyme (P < 0.0001, unpaired t test). (G) Representative TIRF image of a cell expressing GFP-ORP8 before and after treatment with 100 nM A1. Note the disappearance of the ORP8 puncta after A1 treatment.
